DekaBank Deutsche Girozentrale Decreases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DekaBank Deutsche Girozentrale trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 52,257 shares of the company's stock after selling 2,535 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.06% of IDEXX Laboratories worth $21,564,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. United Capital Financial Advisors LLC raised its position in IDEXX Laboratories by 0.9% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after purchasing an additional 22 shares during the last quarter. PDS Planning Inc raised its position in IDEXX Laboratories by 3.9% during the 1st quarter. PDS Planning Inc now owns 641 shares of the company's stock valued at $269,000 after purchasing an additional 24 shares during the last quarter. Gabelli Funds LLC raised its position in IDEXX Laboratories by 5.3% during the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after purchasing an additional 25 shares during the last quarter. Bigelow Investment Advisors LLC raised its position in IDEXX Laboratories by 1.9% during the 1st quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock valued at $596,000 after purchasing an additional 27 shares during the last quarter. Finally, Forum Financial Management LP raised its position in IDEXX Laboratories by 4.9% during the 4th quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after purchasing an additional 29 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director directly owned 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Down 1.4%

IDXX traded down $7.72 during trading on Friday, hitting $533.37. 348,343 shares of the company's stock traded hands, compared to its average volume of 648,553. The company's 50 day simple moving average is $519.68 and its two-hundred day simple moving average is $459.58. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $549.52. The stock has a market capitalization of $42.89 billion, a price-to-earnings ratio of 49.29, a PEG ratio of 3.89 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the business posted $2.71 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of a number of recent analyst reports. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley increased their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Stifel Nicolaus increased their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research report on Wednesday, July 2nd. Leerink Partners increased their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Finally, Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $558.11.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.